|
EP3124018B2 |
Oral Formulations Of Deferasirox
|
24 Apr, 2024
| |
|
EP3023095B2 |
Direct Compression Formulation And Process
|
08 Nov, 2023
| |
|
EP2784084B2 |
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof
|
04 Oct, 2023
| |
|
EP2964202B2 |
Oral Formulations Of Deferasirox
|
31 May, 2023
| |
|
EP3618875B1 |
Combination Therapy
|
05 Apr, 2023
| |
|
EP3858405B1 |
Syringe
|
05 Apr, 2023
| |
|
EP3294283B1 |
Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure
|
08 Mar, 2023
| |
|
EP3805248B1 |
Process For Concentration Of Antibodies And Therapeutic Products Thereof
|
18 Jan, 2023
| |
|
EP3647783B1 |
Identifying Patient Response To S1P Receptor Modulator Administration
|
21 Dec, 2022
| |
|
EP3119423B1 |
Treatment Of Cancer Using Chimeric Antigen Receptor
|
14 Dec, 2022
| |
|
EP3738585B1 |
Direct Compression Formulation And Process
|
14 Dec, 2022
| |
|
EP3067043B1 |
Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor
|
30 Nov, 2022
| |
|
EP3283058B1 |
Ribociclib Tablet
|
16 Nov, 2022
| |
|
EP2959894B1 |
S1P Receptor Modulators For Treating Multiple Sclerosis
|
12 Oct, 2022
| |
|
EP3560498B1 |
Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
|
17 Aug, 2022
| |
|
EP2307457B2 |
Stable And Soluble Antibodies Inhibiting Tnf
|
22 Jun, 2022
| |
|
EP3407945B1 |
Method For Measuring Flow Features In An Inhaler, Inhaler And System
|
04 May, 2022
| |
|
EP3345602B1 |
Rapamycin Derivative For Treating Advanced Solid Tumours
|
06 Apr, 2022
| |
|
EP3656373B1 |
Syringe
|
16 Feb, 2022
| |
|
EP3777834B1 |
Syringe
|
16 Feb, 2022
| |
